Global Startups Insights
Lets your startup
California, Funding News, USA Startup Funding News

BigHat Biosciences Raises $75M in Series C Round

September 24, 2026
By
Olivia Smith
BigHat Biosciences Raises $75M in Series C Round

BigHat Biosciences, a San Mateo, California-based AI-driven biotechnology company, has raised $75 million in Series C funding, bringing its total funding to $223 million.

The round was co-led by DFJ Growth and Premji Invest, with participation from Catalio Capital Management, LG Technology Ventures, Sigmas Group and existing investors including 8VC, Amgen Ventures, Andreessen Horowitz, Eli Lilly and Company, Merck Global Health Innovation Fund and others.

BigHat will use the funding to expand its AI-powered protein design platform and advance its pipeline of AI-designed therapeutics, including BHB810 and BHB299, toward upcoming clinical milestones.

“Our mission is to design transformative therapeutics by combining frontier AI with the autonomous generation of gold-standard biological data,” said Peyton Greenside, co-founder and CEO of BigHat. “This financing will help us advance both sides of that mission: our pipeline of BigHat-designed therapeutics, beginning with BHB810, one of the first AI-designed biologics to reach the clinic, and our leading platform for AI-designed biologics. We look forward to continuing to form partnerships with major technology and life sciences companies and are thrilled to partner with a group of investors who share our vision. With their support, we can continue to scale our platform and pipeline to deliver better medicines to patients more quickly.”

The company combines AI with automated laboratory experimentation to generate biological data at scale and support the design of protein-based medicines. Its lead program, BHB810, is a CDH17-directed antibody-drug conjugate (ADC) for gastric cancer and other advanced gastrointestinal tumors and has entered Phase 1 clinical development.

“BigHat has uniquely enabled reinforcement learning for molecular design with a platform optimized for industry-leading speed, at the scale today’s frontier models need,” said Justin Kao, Partner at DFJ Growth. “This integrated learning loop is a powerful advantage, enabling BigHat to rapidly design and optimize therapeutics with the properties needed for clinical development. The strength of the platform is reflected in both BigHat’s partnerships with pharmaceutical and tech companies and its growing pipeline of next-generation therapeutics. We’re excited to support BigHat as it scales its platform and advances these programs toward patients.”

BigHat has also advanced BHB299, a T-cell engager targeting CEACAM6-expressing solid tumors, with human trials planned for 2027.

The company has partnerships with major pharmaceutical companies including Amgen, Merck, Johnson & Johnson, AbbVie and Lilly, and has raised additional funding through a $44 million Series B extension in 2025.

Recommended Stories for You